Frontiers in Oncology

SEP 8, 2026 · JOURNAL ARTICLE

Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework

Frontiers in Oncology

A critical synthesis and clinical framework addressing heterogeneous stage III NSCLC management in the perioperative immunotherapy era, integrating recent phase III trial evidence with expert consensus on risk-adapted strategies.

SEP 8, 2026 · JOURNAL ARTICLE

Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer

Frontiers in Oncology

A literature review synthesizing evidence on BRCA1/2 as prognostic and predictive biomarkers in ovarian cancer, providing clinical recommendations for testing and treatment selection rather than reporting original trial data.

SEP 8, 2026 · REVIEW

Clinical activity of chidamide-containing regimens after prior PD-1-based therapy in two patients with microsatellite-stable metastatic colorectal cancer: a case series and narrative review

Frontiers in Oncology

A two-patient retrospective case series with mixed responses (one PR, one SD) in a heavily pretreated population; descriptive observations that generate hypotheses rather than test them and are explicitly insufficient to demonstrate efficacy or resistance reversal.

SEP 7, 2026 · JOURNAL ARTICLE

Do not try this at home: patterns and outcomes of radiation dose de-escalation in p16-positive oropharyngeal carcinoma

Frontiers in Oncology

Large national cohort study with hard clinical outcome (overall survival) showing inferior outcomes with dose de-escalation, aligning with recent randomized evidence and supporting current standard-of-care dosing.

SEP 7, 2026 · JOURNAL ARTICLE

The evolving role of radiotherapy in oligometastatic pancreatic cancer: from palliation to disease-modifying multidisciplinary integration

Frontiers in Oncology

Narrative review synthesizing evidence on SBRT in oligometastatic PDAC across six clinical domains, providing recommendations for multidisciplinary integration despite acknowledged paucity of randomized evidence.

SEP 7, 2026 · JOURNAL ARTICLE

Advances in locoregional surgical treatment of de-novo stage IV breast cancer: a review

Frontiers in Oncology

A systematic review synthesizing retrospective and prospective evidence to inform clinical decision-making about locoregional surgery in de-novo stage IV breast cancer, concluding routine surgery is not recommended except for bone-only metastases.

SEP 7, 2026 · REVIEW

Rectovaginal fistulas after radiation therapy: treatment options and outcomes – a narrative review

Frontiers in Oncology

A narrative review synthesizing heterogeneous evidence on treatment options for radiation-induced rectovaginal fistula, offering clinical guidance but acknowledging low overall certainty and lack of direct evidence from RI-RVF populations for most interventions.

SEP 7, 2026 · JOURNAL ARTICLE

First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam

Frontiers in Oncology

Retrospective single-center cohort confirming that CDK4/6 inhibitors with endocrine therapy produce PFS and OS outcomes consistent with pivotal trials in HR+/HER2− metastatic breast cancer, but lacks the design rigor and sample size for practice guidance beyond established use.